What question did this study set out to answer?

The study aims to explore predictive biomarkers for immunotherapy response in advanced non-small cell lung cancer (aNSCLC) patients with low PD-L1 levels.

March 29, 2026Cancer Cell InternationalOpen Access

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

View Full Paper

Ask AI

Bookmark

Authors

MOMario OcchipintiFondazione IRCCS Istituto Nazionale dei Tumori ACAntonella CruoglioInstitute for Experimental Endocrinology and Oncology SMSilvia MarchesiFondazione IRCCS Istituto Nazionale dei Tumori

Discussion

Member takes

Implication

Network analysis predicts immune therapy response in advanced non-small cell lung cancer patients with low PD-L1, suggesting new treatment strategies.

Key Points

The study aims to explore predictive biomarkers for immunotherapy response in advanced non-small cell lung cancer (aNSCLC) patients with low PD-L1 levels.
Analyzed data from the PEOPLE trial (NCT03447678).
Utilized circulating immune profiling (CIP) and gene expression profiling (GEP).
Conducted differential co-expression network analysis to identify hub genes.
Performed patient similarity network analysis to explore patient clusters.
Confirmed that elevated baseline levels of natural killer (NK) cells are linked to better therapeutic response.
Identified 23 hub genes related to immune processes, highlighting CD48's significance.
Found two patient clusters with markedly different survival outcomes.
Demonstrated that the integrated model combining GEP and CIP data outperforms single-layer approaches.

Cite This Study

Occhipinti et al. (2026) studied this question.

synapsesocial.com/papers/69c8c115de0f0f753b39bb5f https://doi.org/10.1186/s12935-026-04268-5

View Full Paper

Ask AI

Bookmark

Implication

Network analysis predicts immune therapy response in advanced non-small cell lung cancer patients with low PD-L1, suggesting new treatment strategies.

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

Discussion

Member takes

Implication

Key Points

Cite This Study

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider